Cargando…
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is the classic progressive fibrosing interstitial lung disease (ILD), but some patients with ILDs other than IPF also develop a progressive fibrosing phenotype (PF-ILD). Information on use and cost of healthcare resources in patients with PF-ILD is l...
Autores principales: | Olson, Amy L., Maher, Toby M., Acciai, Valentina, Mounir, Baher, Quaresma, Manuel, Zouad-Lejour, Leila, Wells, Christopher D., De Loureiro, Lou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467408/ https://www.ncbi.nlm.nih.gov/pubmed/32451950 http://dx.doi.org/10.1007/s12325-020-01380-4 |
Ejemplares similares
-
Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020) -
Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019) -
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019) -
Fibrosing interstitial lung diseases: knowns and unknowns
por: Cottin, Vincent, et al.
Publicado: (2019) -
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)